Compare GSK plc (GSK) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Global X Defense Tech ETF — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Global X Defense Tech ETF trades at $59.73. The key difference: GSK plc pays a 3.49% dividend while Global X Defense Tech ETF pays none, and GSK plc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| GSK | SHLD | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $78.02 |
52-Week Low | $36.20 | $58.20 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
SHLD trades at $59.71, down 0.85% today, with a bearish technical signal from moving averages and ADX indicators. The ETF offers exposure to global defense technology firms amid rising military budgets. Key support is at $59, with resistance at $61. Recent news highlights its role in the defense rearmament theme, though it faces competition from other defense ETFs.
Outlook is mixed: geopolitical tensions and increased defense spending support long-term growth, but technical weakness and competitive ETF landscape pose near-term risks. Investors should weigh the sector's defensive characteristics against current bearish momentum and valuation comparisons with peers like XAR and ITA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
